

# OIE Reference Laboratory Reports Activities

## *Activities in 2019*

**This report has been submitted : 2020-01-14 10:12:52**

<b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b>	Glanders
<b>Address of laboratory:</b>	P.O. Box 597 Dubai UNITED ARAB EMIRATES
<b>Tel.:</b>	+971-4 337.51.65
<b>Fax:</b>	+971-4 336.86.38
<b>E-mail address:</b>	cvrl@cvrl.ae
<b>Website:</b>	www.cvrl.ae
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Priv. Doz. Dr. Dr.habil. Ulrich Wernery
<b>Name (including Title and Position) of OIE Reference Expert:</b>	Priv. Doz. Dr. Dr.habil. Ulrich Wernery
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental

**ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards**

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

Yes

Diagnostic Test	Indicated in OIE Manual (Yes/No)	Total number of test performed last year	
		Nationally	Internationally
Indirect diagnostic tests		Nationally	Internationally
CFT	Yes	5079	1603
Direct diagnostic tests		Nationally	Internationally
Culture	Yes	0	0
PCR	Yes	0	0

**ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards.  
To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.**

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Positive control serum	CFT, ELISA and Western blot	Provided	0	50 ml	Trough private company	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input checked="" type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
DNA extracts from 19 B. mallei strains from horses, donkeys, camels and guinea pigs	Microarray	Provided	0	19 ml	1	<input type="checkbox"/> Africa <input type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input checked="" type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

***ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases***

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

***ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries***

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

Yes

Name of OIE Member Country seeking assistance	Date (month)	No. samples received for provision of diagnostic support	No. samples received for provision of confirmatory diagnoses
BAHRAIN	January -December	477	0
EGYPT	January -December	43	0
JORDAN	January -December	128	0
KUWAIT	January -December	285	2
OMAN	January -December	160	0
SAUDI ARABIA	January -December	495	0
THAILAND	January -December	9	0
SYRIA	January -December	2	0
FRANCE	January -December	0	4

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
KUWAIT	Provided Glanders disease control expertise	e-mail
FRANCE	advised of sample collection and transportation from other countries as well as formulating diagnostic report on glanders	e-mail and verbal

***ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations***

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

Yes

Title of the study	Duration	Purpose of the study	Partners (Institutions)	OIE Member Countries involved other than your country
Assessing the pathogenic ability of genomically altered B. mallei strains which were re isolated from experimentally infected donkeys and guinea pigs	on going	Assessing pathogenic ability	Institut fuer Mikrobiologie der Bundeswehr, Munich	GERMANY
Evaluation of antibody response of sera from experimentally infected donkey's sera with B. mallei using different B. mallei recombinant proteins	on going	To assess the species specific response to different B. mallei recombinant proteins	OIE Glanders Reference Laboratory, Anses, France	FRANCE
Glanders CFT and ELISA testing of melioidosis sera of artificially infected horses	on going	To assess the cross reaction	OIE Glanders Reference Laboratory, Anses, France	FRANCE

***ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases***

11. Did your Laboratory collect epizootiological data relevant to international disease control?

Yes

If the answer is yes, please provide details of the data collected:
Performed serological Glanders tests to diagnose the disease.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:
The results were sent through e-mail to the concerned authorities.

**13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 1

Wernery, U., M.R. Caveney, R. Wernery, R. Raghavan, K. Laroucau, G. Syriac, Sh.M. Thomas, J. John, M. Joseph, Sh. Jose, S. Joseph and P. Woo (2019)

Evaluation of serological responses in horses challenged with Burkholderia pseudomallei using current diagnostic

tests for glanders.

Veterinaria Italiana 55(3), 261-267

Wernery, U., M.R. Caveney, M. Joseph, S. Jose, J. John and J. Kinne (2019)  
Clinical and Pathological Changes of 6 Horses Infected with Burkholderia pseudomallei.  
Austin Journal of Veterinary Science & Animal Husbandry 6(1), ISSN: 2472-3371

b) International conferences: 0

c) National conferences: 0

d) Other:

(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries**

**To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

Yes

a) Technical visits: 3

b) Seminars: 0

c) Hands-on training courses: 7

d) Internships (>1 month): 0

Type of technical training provided (a, b, c or d)	Country of origin of the expert(s) provided with training	No. participants from the corresponding country
c	Indonesia	3
c	Turkey	2
c	Hong Kong	2

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

Yes

Quality management system adopted	Certificate scan (PDF, JPG, PNG format)
ISO 17025:2017	iasc.pdf

16. Is your quality management system accredited?

Yes

Test for which your laboratory is accredited	Accreditation body
African Horse Sickness	IAS, USA
Equine Piroplasmiasis	IAS, USA
Equine Infectious Anaemia	IAS, USA
Equine Viral Arteritis	IAS, USA
Glanders	IAS, USA
Dourine	IAS, USA
CEM	IAS, USA
Brucellosis	IAS, USA
West Nile	IAS, USA
Strangles	IAS, USA
EHV 1&4	IAS, USA
Influenza A virus isolation	IAS, USA
Avian Paramyxovirus Type 1 (APMV-1) virus isolation	IAS, USA
Equine arteritis virus isolation from semen	IAS, USA
MERS-CoV	IAS, USA
ELISA technique for various diseases	IAS, USA
CFT technique for various diseases	IAS, USA
AGID technique for various diseases	IAS, USA

17. Does your laboratory maintain a "biorisk management system" for the pathogen and the disease concerned?

Yes

(See *Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4*)

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

Yes

Title of event	Date (mm/yy)	Location	Role (speaker, presenting poster, short communications)	Title of the work presented
87th OIE General Session at Paris	26-31st May 2019	Paris	Observer	Observer
15th Conference of the OIE Regional commission for the Middle East	10-14 November 2019	United Arab Emirates	Observer	Observer

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

Yes

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

Yes

Title of the project or contract	Scope	Name(s) of relevant OIE Reference Laboratories
Evaluating species specific response to <i>B. mallei</i> recombinant proteins	Standardizing diagnostic test method using Microarray technique	OIE Glanders Reference Laboratory, Anses, France



**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

Yes

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

Purpose for inter-laboratory test comparisons <sup>1</sup>	No. participating laboratories	Region(s) of participating OIE Member Countries
Serological testing competency	3	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

**ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
E-mail correspondence with OIE technical committee	UAE	Amendment of the OIE Glanders chapter
Meeting and discussion with Dr. Axel Colling, expert for OIE collaborating Centre for Diagnostic Test Validation Science	CVRL, UAE	Validation and standardization of Glanders serological tests

25. Additional comments regarding your report: